Carcinoma, Merkel Cell: all 138 studies
Page 2 of 2. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.
- Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell CancerCompletedNCT03798639Phase 1
- Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid TumorsTerminatedNCT03684785Phase 1/2
- A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedNCT03652077Phase 1
- A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesCompletedNCT03629756Phase 1
- DOTATOC PET/CT for Imaging NET PatientsActive, not recruitingNCT03583528
- Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously StudyCompletedNCT03545334Not applicable
- A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 1
- T-VEC in Non-melanoma Skin CancerCompletedNCT03458117Phase 1
- How Microbes and Metabolism May Predict Skin Cancer Immunotherapy OutcomesTerminatedNCT03370861
- Adjuvant Avelumab in Merkel Cell CancerActive, not recruitingNCT03271372Phase 3
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
- Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersActive, not recruitingNCT03212404Phase 1
- QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnNCT03167164Phase 1/2
- Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)Approved for marketingNCT03089658
- Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsActive, not recruitingNCT03074513Phase 2
- Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersActive, not recruitingNCT02978625Phase 2
- Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis FungoidesTerminatedNCT02890368Phase 1
- Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorWithdrawnNCT02831179Phase 1
- Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine AnaloguesCompletedNCT02351128Phase 2
- Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs ObservationCompletedNCT02196961Phase 2
- F16IL2 Plus Paclitaxel in Metastatic Merkel Cell CarcinomaTerminatedNCT02054884Phase 2
- A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell CarcinomaCompletedNCT02035657Phase 1
- Study of the Drug Ipilimumab for Metastatic Merkel Cell CarcinomaWithdrawnNCT01913691Phase 2
- Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell CarcinomaTerminatedNCT01758458Phase 1/2
- A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell CarcinomaCompletedNCT01652547Phase 1
- Videoscopic Versus Open Inguinal Lymphadenectomy for CancerCompletedNCT01526486Not applicable
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
- Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT01155258Phase 1
- Merkel Positron Emission Tomography (PET) ProtocolCompletedNCT01013779Phase 2
- Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsCompletedNCT00655655Phase 1
- Optical Biopsy of Human Skin in Conjunction With Laser TreatmentCompletedNCT00540566
- BB-10901 in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00346385Phase 1
- Oblimersen in Treating Patients With Merkel Cell CarcinomaCompletedNCT00079131Phase 2
- S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell CancerCompletedNCT00068783Phase 2
- Irinotecan in Treating Patients With Advanced Neuroendocrine TumorsCompletedNCT00004922Phase 2
- S9716: Combination Chemotherapy in Treating Patients With Merkel Cell CancerCompletedNCT00003549Phase 2
- Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation TherapyWithdrawnNCT00003514Phase 2
- Indium In 111 Pentetreotide in Treating Patients With Refractory CancerTerminatedNCT00002947Phase 1